RT Journal Article SR Electronic T1 Treatment of diffuse subretinal fibrosis uveitis with rituximab JF British Journal of Ophthalmology JO Br J Ophthalmol FD BMJ Publishing Group Ltd. SP 153 OP 154 DO 10.1136/bjophthalmol-2013-304686 VO 99 IS 2 A1 Kurt Spiteri Cornish A1 Lucia Kuffova A1 John V Forrester YR 2015 UL http://bjo.bmj.com/content/99/2/153.abstract AB Diffuse subretinal fibrosis uveitis (DUS) syndrome is a rare form of granulomatous multifocal choroiditis (MFC) characterised by enlarging areas of subretinal fibrosis (SRF) which coalesce with subsequent macular involvement and visual loss. First described by Palestine, DUS carries a poor visual prognosis despite use of high-dose corticosteroids and systemic immunosuppression. We report two cases of bilateral DUS successfully treated with rituximab. We believe given the B-cell predominance in the underlying pathogenesis of the disease, rituximab should be considered first line in the management of this potentially devastating disease.